<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20130409012953N4</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2023-08-21</date_registration>
      <primary_sponsor>Deputy of Research of Iran University of Medical Sciences</primary_sponsor>
      <public_title>Effect of dry needling in treatment of scar</public_title>
      <acronym></acronym>
      <scientific_title>The effectiveness of dry needling on scar tissue: a randomized controlled trial</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2023-09-23</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>80</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/66082</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: All eligible patients with hypertrophic scar tissue will be randomized to an intervention group (dry needling in addition to routine physical therapy) and a control group (sham dry needling in addition to routine physical therapy) with a ratio of 1:1. Randomized allocation will be performed by using permuted block randomization method, which consists of four-letter blocks made of letters A and B. Then, the random treatment list that will be obtained at the end of the random allocation task will be placed in letters A and B inside the sealed and numbered envelopes (A letter indicates true dry needling and letter B indicates sham dry needling). Six four-letter blocks of letters A and B will be created in which the letter A or B is not repeated more than twice in each block. These blocks include AABB, ABAB, BBAA, BAAB, ABBA, BABA. Considering that each block represents 4 participants and in the current study, 80 participants are needed, 20 blocks of four are required. Referring to a table of 20 random numbers between 1 to 6 (the number of blocks created above), the selection process will be performed using Google Random Number Generator. The random assignment process will be performed by someone outside the research team before the study begins. After the initial evaluation of the patient by the examiner, the numbered envelopes will be presented to him/her according to the ordinal number of each person admitted to the study. Finally, after each patient enters the treatment sessions, the therapist will adjust the treatment interventions based on the letters in the envelope. Patients are asked not to provide their grouping information to the assessor to prevent data contamination, Blinding description: Individuals in the control group will be in the same position as those in the intervention group, with needles placed superficially in an area slightly further away from the scar tissue. Additionally, the data analyst will be unaware of the grouping of the participants, and each participant will be identified by a unique numerical code.</study_design>
      <phase>3</phase>
      <hc_freetext>Scar tissue.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Dry needling therapy in the true dry needling group along with routine physiotherapy is performed by inserting a 2 cm Dung bang brand needle at an angle of about 15 degrees to the skin surface into the scar tissue and rotating it to separate the tissue adhesions. This is done along the path of the scar. The number of treatment sessions for patients is 6 sessions, which will be performed 3 sessions per week for two weeks. The assessment of participants will be done once before starting the treatment, immediately after the end of the treatment, and two weeks after the last treatment session. Routine physiotherapy treatment for patients with scars in both groups includes using kinesiology taping along with infrared (for 20 minutes) at a distance of 30 cm from the scar tissue. Intervention 2: Control group:  In the sham dry needling treatment group along with routine physiotherapy, the patient's condition is completely similar to the real dry needling treatment group, except that instead of a real needle, a sham needle is used. The needle is inserted superficially at a point further away from the scar tissue and is removed after 20 minutes. Routine physiotherapy in this group is similar to the main intervention group.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
The raw data of research and its analysis will be available to the researcher if they request it.

When:
After six months from the date of publication.

To whom:
The data will be available for physical therapists working in academic institutions and also clinicians working in the field of dry needling.

Conditions:
The raw data and results of this study can be used in future relevant systematic reviews. Thus, the raw data and results of this study will be available for researchers working in the field of dry needling.

Where to obtain:
Applicants can contact Dr. Mohammad Reza Pourahmadi by email. Email address: pourahmadipt@gmail.com

How to obtain:
Applicants should explain in detail about their project and how the data/documents of this study will be used in their project. Then, the data/documents files will be sent by email to applicants on request. This process may takes 10-12 working days.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Mohammadreza Pourahmadi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Madadkaran (Nezam) St., Shahnazari St., Madar Sq., Mirdamad Blvd. Tehran.</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1545913487</zip>
        <telephone>+98 21 2222 2059</telephone>
        <email>pourahmadipt@gmail.com</email>
        <affiliation>Iran University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Mohammadreza Pourahmadi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Madadkaran (Nezam) St., Shahnazari St., Madar Sq., Mirdamad Blvd. Tehran.</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1545913487</zip>
        <telephone>+98 21 2222 2059</telephone>
        <email>pourahmadipt@gmail.com</email>
        <affiliation>Iran University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
      <country2>United States of America</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Longitudinal scar tissue older than six weeks
No contraindication for joint active and passive movements near the scar tissue
Age between 20-60 years</inclusion_criteria>
      <agemin>20 years</agemin>
      <agemax>60 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Trypanophobia
Skin problems (such as infection, wounds, atopic dermatitis)</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>L90.5</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Scar conditions and fibrosis of skin</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Rehabilitation</i_code>
      <i_code>Placebo</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Dry needling therapy in the true dry needling group along with routine physiotherapy is performed by inserting a 2 cm Dung bang brand needle at an angle of about 15 degrees to the skin surface into the scar tissue and rotating it to separate the tissue adhesions. This is done along the path of the scar. The number of treatment sessions for patients is 6 sessions, which will be performed 3 sessions per week for two weeks. The assessment of participants will be done once before starting the treatment, immediately after the end of the treatment, and two weeks after the last treatment session. Routine physiotherapy treatment for patients with scars in both groups includes using kinesiology taping along with infrared (for 20 minutes) at a distance of 30 cm from the scar tissue.</i_keyword>
      <i_keyword>Control group:  In the sham dry needling treatment group along with routine physiotherapy, the patient's condition is completely similar to the real dry needling treatment group, except that instead of a real needle, a sham needle is used. The needle is inserted superficially at a point further away from the scar tissue and is removed after 20 minutes. Routine physiotherapy in this group is similar to the main intervention group.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>The flexibility of the scar tissue. Timepoint: At the start of the study (prior to the intervention), immediately following the final treatment session, and two weeks after the completion of the treatment sessions. Method of measurement: Tissue compliance meter.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Active and passive joint range of motion. Timepoint: At the start of the study (prior to the intervention), immediately following the final therapy session, and two weeks after the completion of the treatment sessions. Method of measurement: Universal goniometer.</sec_outcome>
      <sec_outcome>Pain. Timepoint: At the start of the study (prior to the intervention), immediately following the final therapy session, and two weeks after the completion of the treatment sessions. Method of measurement: Numeric pain rating scale.</sec_outcome>
      <sec_outcome>Functional disability. Timepoint: At the start of the study (prior to the intervention), immediately following the final therapy session, and two weeks after the completion of the treatment sessions. Method of measurement: SF-36 questionnaire.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Deputy of Research of Iran University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2022-08-27</approval_date>
        <contact_name>Ethics committee of Iran University of Medical Sciences</contact_name>
        <contact_address>Madadkaran (Nezam) St., Shahnazari St., Madar Sq., Mirdamad Blvd. Tehran. Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
